CTMX•CytomX Therapeutics’ Q3 2026 revenue fell 72% year over year to $1.7 million, while operating expenses rose 16% to $25.2 million. The company reported $348 million in quarter-end cash, cash equivalents and investments, with runway expected into the second half of 2028.
CytomX Therapeutics reported Q3 2026 revenue of $1.7 million, down 72% year over year, and operating expenses of $25.2 million, up 16%. Quarter-end cash, cash equivalents and investments totaled $348 million, with the company expecting a cash runway into the second half of 2028. A Varseta-M colorectal cancer monotherapy data update is expected in January 2027, and a first registrational study could begin in the first half of 2027.
